Melanoma and Melanoma In-Situ Diagnosis after Excision of Atypical Intraepidermal Melanocytic Proliferation (AIMP): A Retrospective Cross-Sectional Analysis

Publication date: Available online 14 January 2019

Source: Journal of the American Academy of Dermatology

Author(s): Nina R. Blank, Brian P. Hibler, Ian W. Tattersall, Courtney J. Ensslin, Erica H. Lee, Stephen W. Dusza, Kishwer S. Nehal, Klaus J. Busam, Anthony M. Rossi

Abstract

Background

There is little evidence to guide surgical management of biopsies yielding the histologic descriptor "atypical intraepidermal melanocytic proliferation" (AIMP).

Objective

Determine frequency of and factors associated with melanoma and melanoma in-situ (MIS) diagnoses after excision of AIMP and evaluate margins used to completely excise AIMP.

Methods

Retrospective, cross-sectional study of 1127 biopsies reported as AIMP and subsequently excised within one academic institution.

Results

Melanoma (in-situ, stage 1A) was diagnosed after excision in 8.2% (92/1127) of AIMP samples. Characteristics associated with melanoma/MIS diagnosis included age 60-79 (OR 8.1, 95% CI 2.5-26.2), age >80 (OR 7.2, 95% CI 1.7-31.5), head/neck location (OR 4.9, 95% CI 3.1-7.7), clinical lesion partially biopsied (OR 11.0, 95% CI 6.7-18.1), and lesion extending to deep biopsy margin (OR 15.1, 95% CI 1.7-136.0). Average surgical margin used to excise AIMP lesions was 4.5mm (SD 1.8).

Limitations

Single-site, retrospective, observational study; interobserver variability across dermatopathologists.

Conclusion

Dermatologists and pathologists can endeavor to avoid ambiguous melanocytic designations whenever possible through excisional biopsy technique, interdisciplinary communication, and ancillary studies. In the event of AIMP biopsy, physicians should consider the term a histological description rather than a diagnosis, and, during surgical planning, use clinicopathologic correlation while bearing in mind factors that might predict true melanoma/MIS.

http://bit.ly/2TSBnG2